Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.
| Revenue (Most Recent Fiscal Year) | $144.29M |
| Net Income (Most Recent Fiscal Year) | $-13.58M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.49 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -0.62% |
| Net Margin (Trailing 12 Months) | -0.62% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -0.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.82 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.53 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.66 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.22 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.09 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.02 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 183.32M |
| Free Float | 172.57M |
| Market Capitalization | $223.64M |
| Average Volume (Last 20 Days) | 1.33M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.86% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |